Clinical Research Directory
Browse clinical research sites, groups, and studies.
Liraglutide in the Prevention of Type 2 Diabetes After Gestational Diabetes
Sponsor: Turku University Hospital
Summary
Obese women with history of gestational diabetes are in great danger to develop type 2 diabetes (T2D) within 5-10 years after delivery. Aim of the study is to investigate if 12 months' liraglutide treatment could decrease the risk of T2D in obese women who have had gestational diabetes. The women are randomized either to liraglutide (Victoza ® 1.8 mg) or placebo group, once daily. Same laboratory tests are taken and instructions given at baseline 6 month and one year. After one year visits once a year until 5 years with same laboratory tests and measurements are taken.
Key Details
Gender
FEMALE
Age Range
Any - Any
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2020-02-07
Completion Date
2027-12
Last Updated
2023-12-06
Healthy Volunteers
Yes
Conditions
Interventions
Liraglutide 6 MG/ML [Victoza]
Starting dose of liraglutide 0.6 mg will be administered for one week, after which dose will be escalated to liraglutide 1.2 mg for one week and thereafter liraglutide 1.8 mg s.c. daily injections.
Placebos
Starting dose of placebo 0.1 ml will be administered for one week, after which dose will be escalated to placebo 0.2 ml for one week and thereafter placebo 0.3 ml s.c. daily injections.
Locations (1)
Turku University Hospital
Turku, Finland